secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-08-26T23:59:59+00:00
Accession:  0001193125-24-206655
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics appoints Brett Kaplan as COO with equity grants
------------------------------------------------------------------

- Brett Kaplan, M.D., appointed Chief Operating Officer effective August 26, 2024.
- Base salary of $500,000/year; eligible for annual bonus up to 45% of base salary.
- Granted option to purchase 465,000 shares and 77,500 RSUs under 2021 Equity Incentive Plan.
- Option vests 25% at one year then monthly over 3 years; RSUs vest 25% annually over 4 years.
- Severance: 9 months salary (non-CIC) or 12 months plus target bonus (CIC), plus COBRA and equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/0001193125-24-206655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524206655/d866047d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-206655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer